* EPIXIS *
2003 - IDF
Paris
www.epixis.com Discovery, Immunology
Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines
Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV
Clients: Pharmaceutical industry
contact@epixis.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.: Frisen (Charlotte)
Sc.Dir.:
Fin.Dir.:
BusDev:
Financers: Génopole 1er Jour | Turnover (M€) : 0.09 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Virus
Position : Preclin
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .09 | Website under construction since May 2008 | INFO | [5 years] |
| 2003 .07 | Company founded by Prof. David Klatzmann [AP-HP], Prof. François-Loïc Cosset [Inserm], Frédéric Tanguy [Institut Pasteur] | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
